(Q38386664)

English

Novel Humanitarian Aid Program: The Glivec International Patient Assistance Program-Lessons Learned From Providing Access to Breakthrough Targeted Oncology Treatment in Low- and Middle-Income Countries

scientific article published on 23 September 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

Novel Humanitarian Aid Program: The Glivec International Patient Assistance Program-Lessons Learned From Providing Access to Breakthrough Targeted Oncology Treatment in Low- and Middle-Income Countries (English)

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

lessons learned

1 reference

based on heuristic

inferred from title

author name string

Pat Garcia-Gonzalez

1

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

Paula Boultbee

2

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

David Epstein

3

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

publication date

23 September 2015

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

Journal of global oncology

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

1

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

1

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

37-45

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

Improving access to care in low and middle-income countries: institutional factors related to enrollment and patient outcome in a cancer drug access program.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5551649

6 September 2017

Effect of the Affordable Medicines Facility--malaria (AMFm) on the availability, price, and market share of quality-assured artemisinin-based combination therapies in seven countries: a before-and-after analysis of outlet survey data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5551649

6 September 2017

Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5551649

6 September 2017

Expansion of cancer care and control in countries of low and middle income: a call to action

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5551649

6 September 2017

Benefits of global partnerships to facilitate access to medicines in developing countries: a multi-country analysis of patients and patient outcomes in GIPAP

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5551649

6 September 2017

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5551649

6 September 2017

Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5551649

6 September 2017

Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5551649

14 September 2017

International patterns of childhood chronic myeloid leukemia: comparisons between the United States and resource-restricted nations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5551649

31 August 2018

Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5551649

31 August 2018

Adherence to treatment is a complex and multifaceted issue that can substantially alter the outcome of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5551649

31 August 2018

United States life tables, 2006.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5551649

31 August 2018

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5551649

31 August 2018

Gleevec for the treatment of chronic myelogenous leukemia: US. Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug status

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5551649

31 August 2018

Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5551649

31 August 2018

Scaling up cancer diagnosis and treatment in developing countries: what can we learn from the HIV/AIDS epidemic?

1 reference

https://pubmed.ncbi.nlm.nih.gov/28804770

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/28804770

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/28804770

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JGO.2015.000570

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38386664&oldid=1536912179"